

Sanofi
Form 6-K
September 19, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2011

Commission File Number: 001-31368

SANOFI

(Translation of registrant's name into English)

Edgar Filing: Sanofi - Form 6-K

174, avenue de France, 75013 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If Yes marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_____

In September 2011, Sanofi issued the press releases attached hereto as Exhibit 99.1 to 99.3 which are incorporated herein by reference.

Exhibit List

| Exhibit | No. | Description |
|--------------|-----|--|
| Exhibit 99.1 | | Press release dated September 12, 2011: Lyxumia® (lixisenatide) One-Step Regimen as Effective as Two-Step Regimen in Improving Glycemic Control in Type 2 Diabetes. |
| Exhibit 99.2 | | Press release dated September 12, 2011: Initiation of Lantus leads to better glycemic control at similar weight gain versus other comparators in patients with Type 2 Diabetes |
| Exhibit 99.3 | | Press release dated September 19, 2011: U.S. District Court Rules in Favor of Sanofi U.S. in Eloxatin® Patent Litigation |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: September 19, 2011

SANOFI

By /S/ John Felitti
Name: John Felitti
Title: Associate Vice President,
Corporate Law, Financial & Securities Law

Exhibit Index

| Exhibit | No. | Description |
|--------------|-----|--|
| Exhibit 99.1 | | Press release dated September 12, 2011: Lyxumia® (lixisenatide) One-Step Regimen as Effective as Two-Step Regimen in Improving Glycemic Control in Type 2 Diabetes. |
| Exhibit 99.2 | | Press release dated September 12, 2011: Initiation of Lantus leads to better glycemic control at similar weight gain versus other comparators in patients with Type 2 Diabetes |
| Exhibit 99.3 | | Press release dated September 19, 2011: U.S. District Court Rules in Favor of Sanofi U.S. in Eloxatin® Patent Litigation |